Berkeley, CA, United States

Dynavax Technologies

www.dynavax.com
Berkeley, CA, United States
SEARCH FILTERS
Time filter
Source Type

The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


News Article | April 18, 2017
Site: marketersmedia.com

Wiseguyreports.Com Adds “ALL Vaccine -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies the ALL Vaccine market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the ALL Vaccine market by product type and applications/end industries. The global ALL Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of ALL Vaccine. Europe also play important roles in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of XX. Pfizer, Inc., Glaxosmithkline, PLC., Merck & Co., Inc., Novarits, Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Inc., Johnson & Johnson, Medimmune, LLC. (A Subsidiary of Astrazeneca), Astellas Pharma Inc., Mitsubishi Tanabe, Dynavax Technologies, Novavax Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of ALL Vaccine in these regions, from 2012 to 2022 (forecast), covering On the basis of product, the ALL Vaccine market is primarily split into Vaccinia Measles, mumps, rubella Varicella Influenza Rotavirus Zoster Yellow Fever Polio Hepatitis A Rabies BCG Diphtheria, tetanus Hepatitis B Haemophilus influenzae type b Pertussis Human papillomavirus Meningococcal Pneumococcal On the basis on the end users/applications, this report covers For Adult For Child Global ALL Vaccine Sales Market Report 2017 1 ALL Vaccine Market Overview 1.1 Product Overview and Scope of ALL Vaccine 1.2 Classification of ALL Vaccine by Product Category 1.2.1 Global ALL Vaccine Sales (K Units) and Growth (%) Comparison by Types (2012-2022) 1.2.2 Global ALL Vaccine Sales Market Share (%) by Types in 2016 1.2.3 Vaccinia 1.2.4 Measles, mumps, rubella 1.2.5 Varicella 1.2.5 Influenza 1.2.5 Rotavirus 1.2.6 Zoster 1.2.7 Yellow Fever 1.2.8 Polio 1.2.9 Hepatitis A 1.2.10 Rabies 1.2.11 BCG 1.2.12 Diphtheria, tetanus 1.2.13 Hepatitis B 1.2.14 Haemophilus influenzae type b 1.2.15 Pertussis 1.2.16 Human papillomavirus 1.2.17 Meningococcal 1.2.18 Pneumococcal 9 Global ALL Vaccine Players Profiles and Sales Data 9.1 Pfizer, Inc. 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 ALL Vaccine Product Category, Application and Specification 9.1.2.1 Product A 9.1.2.2 Product B 9.1.3 Pfizer, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Glaxosmithkline, PLC. 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 ALL Vaccine Product Category, Application and Specification 9.2.2.1 Product A 9.2.2.2 Product B 9.2.3 Glaxosmithkline, PLC. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Merck & Co., Inc. 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 ALL Vaccine Product Category, Application and Specification 9.3.2.1 Product A 9.3.2.2 Product B 9.3.3 Merck & Co., Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.3.4 Main Business/Business Overview 9.4 Novarits 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 ALL Vaccine Product Category, Application and Specification 9.4.2.1 Product A 9.4.2.2 Product B 9.4.3 Novarits ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.4.4 Main Business/Business Overview 9.5 Sanofi Pasteur 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 ALL Vaccine Product Category, Application and Specification 9.5.2.1 Product A 9.5.2.2 Product B 9.5.3 Sanofi Pasteur ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.5.4 Main Business/Business Overview 9.6 CSL Limited 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 ALL Vaccine Product Category, Application and Specification 9.6.2.1 Product A 9.6.2.2 Product B 9.6.3 CSL Limited ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.6.4 Main Business/Business Overview 9.7 Emergent Biosolutions, Inc. 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 ALL Vaccine Product Category, Application and Specification 9.7.2.1 Product A 9.7.2.2 Product B 9.7.3 Emergent Biosolutions, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.7.4 Main Business/Business Overview 9.8 Johnson & Johnson 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 ALL Vaccine Product Category, Application and Specification 9.8.2.1 Product A 9.8.2.2 Product B 9.8.3 Johnson & Johnson ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.8.4 Main Business/Business Overview 9.9 Medimmune, LLC. (A Subsidiary of Astrazeneca) 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 ALL Vaccine Product Category, Application and Specification 9.9.2.1 Product A 9.9.2.2 Product B 9.9.3 Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.9.4 Main Business/Business Overview 9.10 Astellas Pharma Inc. 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 ALL Vaccine Product Category, Application and Specification 9.10.2.1 Product A 9.10.2.2 Product B 9.10.3 Astellas Pharma Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.10.4 Main Business/Business Overview 9.11 Mitsubishi Tanabe 9.12 Dynavax Technologies 9.13 Novavax For more information, please visit https://www.wiseguyreports.com/sample-request/1193278-global-all-vaccine-sales-market-report-2017

Loading Dynavax Technologies collaborators
Loading Dynavax Technologies collaborators